Stockscreener 앱 받기
23.28
2.59%
-0.62
시간 외 거래:
23.28
전일 마감가:
$23.90
열려 있는:
$23.69
하루 거래량:
1.42M
Relative Volume:
1.11
시가총액:
$1.92B
수익:
-
순이익/손실:
$-154.65M
주가수익비율:
-9.7873
EPS:
-2.3786
순현금흐름:
$-142.43M
1주 성능:
-13.75%
1개월 성능:
-17.03%
6개월 성능:
-40.72%
1년 성능:
+38.99%
1일 변동 폭
$23.08
$24.11
1주일 범위
$23.08
$28.65
52주 변동 폭
$10.44
$47.65
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
명칭
Mineralys Therapeutics Inc
전화
(888) 378-6240
주소
150 N. RADNOR CHESTER RD., RADNOR
Compare MLYS vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
23.28 | 1.97B | 0 | -154.65M | -142.43M | -2.3786 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-11 | 개시 | Jefferies | Hold |
| 2024-07-10 | 개시 | H.C. Wainwright | Buy |
| 2024-04-02 | 개시 | Goldman | Buy |
| 2023-03-07 | 개시 | BofA Securities | Buy |
| 2023-03-07 | 개시 | Credit Suisse | Outperform |
| 2023-03-07 | 개시 | Evercore ISI | Outperform |
| 2023-03-07 | 개시 | Guggenheim | Buy |
| 2023-03-07 | 개시 | Stifel | Buy |
| 2023-03-07 | 개시 | Wells Fargo | Overweight |
모두보기
Mineralys Therapeutics Inc 주식(MLYS)의 최신 뉴스
Mineralys Therapeutics grants inducement equity awards to two new employees - MSN
Why Mineralys Therapeutics Shares Are Sliding Today - TipRanks
Research Analysts Issue Forecasts for MLYS Q1 Earnings - MarketBeat
Mineralys reports 2025 results, advances hypertension drug review - MSN
Rodman David Malcom sells Mineralys Therapeutics (MLYS) stock for $10,696 - Investing.com Canada
Insider sale notices at Mineralys Therapeutics (NASDAQ: MLYS) detail multiple Q1 2026 transactions - Stock Titan
Mineralys Therapeutics (MLYS) CMO exercises stock options and sells shares - Stock Titan
Mineralys Reports 2025 Results, Advances Hypertension Drug Review - MyChesCo
Risk Check: Will Mineralys Therapeutics Inc outperform tech stocksTrade Volume Report & Growth-Oriented Investment Plans - baoquankhu1.vn
HC Wainwright Has Positive Outlook of MLYS FY2029 Earnings - MarketBeat
Holocene Advisors LP Buys Shares of 1,205,377 Mineralys Therapeutics, Inc. $MLYS - MarketBeat
David Malcom Rodman Sells 14,058 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock - MarketBeat
David Malcom Rodman Sells 6,348 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock - MarketBeat
Mineralys Therapeutics MLYS CMO sells shares worth $542,973 By Investing.com - Investing.com Canada
Mineralys Therapeutics CMO Sells Over 20,000 Shares - TradingView
Mineralys (MLYS) CMO exercises options, sells 20,406 shares under 10b5-1 plan - Stock Titan
Mineralys Therapeutics reports inducement awards under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New Mineralys hire gets stock options and RSUs vesting over four years - Stock Titan
Mineralys: Advancing Lorundrostat Toward Commercialization in Uncontrolled Hypertension With Differentiated Efficacy and Safety - TipRanks
HighVista Strategies LLC Boosts Position in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Farallon Capital Management LLC Purchases Shares of 1,673,053 Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Cinctive Capital Management LP Has $2.72 Million Stock Holdings in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys (MLYS) Q4 2025 Earnings Call Transcript - AOL.com
Mineralys Reports Strong Phase 3 Results for Lorundrostat in High-Risk Hypertension Patients - MSN
Boothbay Fund Management LLC Increases Position in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys Therapeutics, Inc. $MLYS Shares Sold by 22NW LP - MarketBeat
Mineralys Therapeutics (NASDAQ:MLYS) Upgraded to Hold at Wall Street Zen - MarketBeat
Losartan Side Effects You Shouldn’t Ignore—Plus One That May Actually Help - AOL.com
Mineralys Therapeutics, Inc. $MLYS Shares Purchased by Suvretta Capital Management LLC - MarketBeat
Integral Health Asset Management LLC Lowers Stake in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys Therapeutics Charts Path After NDA Acceptance - TipRanks
Mineralys Therapeutics (MLYS) makes progress with FDA for hypertension - MSN
Jefferies Maintains MLYS at Hold for Mineralys Therapeutics, Inc. March 2026 - Meyka
David Rodman sells multiple Mineralys (NASDAQ: MLYS) share tranches in Q1 2026 - Stock Titan
Jefferies cuts Mineralys Therapeutics price target on drug concerns - Investing.com UK
Mineralys Therapeutics (MLYS) Makes Progress With FDA For Hypertension - Insider Monkey
Jefferies cuts Mineralys Therapeutics price target on drug concerns By Investing.com - Investing.com Australia
Mineralys Therapeutics price target raised to $51 from $46 at BofA - TipRanks
Stifel reiterates Buy rating on Mineralys stock, $52 target - Investing.com Nigeria
BofA raises Mineralys Therapeutics stock price target on NDA progress By Investing.com - Investing.com Nigeria
Mineralys: Big Pharma Threatens To Undermine Likely Hypertension Drug Approval (MLYS) - Seeking Alpha
Stifel reiterates Buy rating on Mineralys stock, $52 target By Investing.com - Investing.com Canada
BofA raises Mineralys Therapeutics stock price target on NDA progress - Investing.com
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q4 2025 Earnings Call Transcript - Insider Monkey
Mineralys Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Here's Why Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock to Buy - MSN
Decoding Mineralys Therapeutics Inc (MLYS): A Strategic SWOT Insight - GuruFocus
Decoding Mineralys Therapeutics Inc (MLYS): A Strategic SWOT Ins - GuruFocus
Mineralys Therapeutics Inc (MLYS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):